<DOC>
	<DOCNO>NCT02772588</DOCNO>
	<brief_summary>The purpose study determine whether anti-testosterone medication , administer , , high-dose , precision radiation , effective prevent prostate cancer return .</brief_summary>
	<brief_title>AASUR High Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Histological cytologic evidence adenocarcinoma prostate confirm local institution . At least one follow : Two high risk feature OR Gleason score 810 PSA ≥20 ng/mL within two month prior registration Clinical Stage ≥T3 disease , determined standard digital rectal examination ( DRE ) Radiographic stage ≥T3 disease determine ≥75 % probability extracapsular extension seminal vesicle invasion per read radiologist Serum testosterone ≥ 240 ng/dL determine within 2 month prior registration KPS ≥ 70 % IPSS ( International Prostate Symptom Score ) ≤ 20F Patient must available followup Laboratory test finding within 28 day study registration : Adequate hepatic function : Serum bilirubin ≤ 1.5 time upper institutional limit normal ( ULN ) . Patients history Gilbert 's syndrome may enrol total bilirubin &lt; 3 mg/dL predominance indirect bilirubin . If total bilirubin &gt; 1.5 x institutional ULN , direct indirect bilirubin measure direct bilirubin ≤ 1.5 x institutional ULN , patient eligible participate SGPT ( ALT ) SGOT ( AST ) ≤ 2.5 x ULN Adequate renal function serum creatinine &lt; 2.0 x institutional ULN Adequate hematologic function : Absolute neutrophil count ≥ 1500 cell/mm3 Platelets ≥ 100,000 cells/mm3 ( independent blood transfusion and/or growth factor within 3 month prior registration ) Hemoglobin value ≥9 g/dL Screening Visit ( independent blood transfusion and/or growth factor within 3 month prior registration ) Electrolytes ( serum calcium , sodium ) within normal limit Serum albumin ≥ 3.0 g/dL Serum potassium ≥ 3.5 mmol/L Patients pelvic and/or retroperitoneal lymph node &lt; 1.5 cm short axis eligible consider definitive metastasis Willing able provide write informed consent HIPAA authorization release personal health information NOTE : HIPAA authorization may either include informed consent obtain separately Males 18 year age The effect ARN509 , abiraterone , leuprolide stereotactic , ultrahypofractionated radiation develop human fetus recommend therapeutic dose unknown . Men ( include men vasectomy ) must agree use adequate contraception ( condom another effective method birth control ) prior registration , duration study participation , least 3 month thereafter . Men must also agree donate sperm duration study participation , least 3 month thereafter . Radiographic evidence metastatic disease Patients one positive lymph node determine radiographic assessment MRI CT NOTE : lymph node note MRI CT &gt; 1.5 cm short axis require review local reference radiologist per institutional RECIST review practice . If lymph node consider suspicious repeat review , must confirm negative study participation Prior treatment prostate cancer ; include prior surgery ( include TURP ) , chemotherapy , radiation , antiandrogen therapy . Prior use nonsteroidal antiandrogens ( e.g. , bicalutamide , flutamide , nilutamide ) , steroidal antiandrogens ( megestrol acetate , cyproterone acetate ) , AR partial agonist , ketoconazole , chemotherapy , immunotherapy , estrogens , radiopharmaceutical within 3 month registration administration study treatment Prior use herbal product alternative therapy may decrease PSA level may hormonal antiprostate cancer activity ( e.g. , saw palmetto , PCSPES , PCHOPE , St. John 's wort , selenium supplement , grape seed extract , etc . ) within 3 month registration administration study treatment Prior treatment medication know low seizure threshold within 4 week registration ( see section 5.5.2 ARN509 list prohibit medication ) History another malignancy within previous 3 year except follow : adequately treat basal cell squamous cell skin cancer , superficial bladder cancer , adequately treated Stage I Stage II cancer currently complete remission , cancer complete remission least 3 year Severe hepatic impairment ( ChildPugh Class C ) Concurrent treatment strong CYP3A4 inducer ( e.g. , phenytoin , carbamazepine , rifampin , rifabutin , rifapentine , phenobarbital ) Major surgery within 4 week registration Presence pacemaker Active infection medical condition would make prednisone use contraindicate A know hypersensitivity abiraterone acetate , ARN509 , prednisone and/or excipients Severe unstable angina , myocardial infarction , symptomatic congestive heart failure , arterial venous thromboembolic event ( e.g. , pulmonary embolism , cerebrovascular accident include transient ischemic attack ) , clinically significant ventricular arrhythmia within 6 month prior registration . Seizure know condition may predispose seizure ( include limit prior stroke , transient ischemic attack , loss consciousness within 1 year prior randomization , brain arteriovenous malformation ; intracranial mass schwannomas meningiomas cause edema mass effect ) Any ECG change interfere QT interval interpretation ( e.g. , leave bundle branch block , frequent premature ventricular contraction ) Prolonged QTc &gt; 450ms Screening Visit Uncontrolled diabetes , heart disease , hypertension Gastrointestinal disorder affect absorption Active symptomatic viral hepatitis chronic liver disease History pituitary adrenal dysfunction Active Infection ( e.g. , human immunodeficiency virus [ HIV ] viral hepatitis ) medical condition would make prednisone/prednisolone corticosteroid ) use contraindicate Patients Crohn 's disease ulcerative colitis Patients tolerate MRI Inability fiducial marker place Any condition opinion investigator , would preclude participation study Enrollment concurrently another investigational drug study within 4 week registration Concurrent treatment strong CYP3A4 inducer ( e.g. , phenytoin , carbamazepine , rifampin , rifabutin , rifapentine , phenobarbital )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ARN-509</keyword>
	<keyword>Abiraterone</keyword>
	<keyword>Leuprolide</keyword>
	<keyword>Intensity-Modulated Image-Guided Radiation Therapy</keyword>
	<keyword>15-334</keyword>
	<keyword>apalutamide ,</keyword>
	<keyword>JNJ-56021927</keyword>
</DOC>